TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations
Thomas Newsom-Davis, Barbara Melosky, Rebecca S. Heist, Shun Lu, Giulia Pasello, Xiwei Chen, Marta Stachowiak, Pavlo Lyfar, Alessandra Forcina, Suresh S. Ramalingam · 2026
Read TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations by Thomas Newsom-Davis, Barbara Melosky, Rebecca S. Heist, Shun Lu, Giulia Pasello, Xiwei Chen, Marta Stachowiak, Pavlo Lyfar, Alessandra Forcina, Suresh S. Ramalingam (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12883807.txt.
Description
Thomas Newsom-Davis and co-authors lay out a phase three trial of a two-drug first treatment for advanced lung cancer in this 2025 paper. The patients have nonsquamous tumors with high PD-L1 levels and no targetable gene faults. Standard immunotherapy helps many, but some resist it from the start.
About six hundred seventy-five adults will be assigned to a drug pair, one drug alone, or the standard drug. The pair joins an antibody-drug conjugate aimed at a tumor surface protein with a two-target immune antibody. Main measures are how long the cancer stays controlled and overall survival in a biomarker-defined group. Response rates, patient reports, and safety are also tracked. The trial is registered and recruiting across many centers.
Catalog record
| CREATOR | Thomas Newsom-Davis, Barbara Melosky, Rebecca S. Heist, Shun Lu, Giulia Pasello, Xiwei Chen, Marta Stachowiak, Pavlo Lyfar, Alessandra Forcina, Suresh S. Ramalingam |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |